<blockquote class=”twitter-tweet” data-media-max-width=”560″><p lang=”en” dir=”ltr”>Cybertruck towing 3000lbs to the dunes was a breeze! <a href=”https://twitter.com/Tesla?ref_src=twsrc%5Etfw”>@Tesla</a> <a href=”https://twitter.com/cybertruck?ref_src=twsrc%5Etfw”>@cybertruck</a> <a href=”https://twitter.com/elonmusk?ref_src=twsrc%5Etfw”>@elonmusk</a> <a…
Browsing: Chronic Lymphocytic Leukemia
David J. Andorsky, MD, an Associate Chair for US Oncology Hematology Research and a member of the Rocky Mountain Cancer’s…
Jeff Sharman, MD, a medical oncologist at the Willamette Ballet Cancer Institute and Research Center, also serving as the Medical…
By: Christopher Flowers, MD Date: 09/22/2023 Dr. Christopher Flowers of MD Anderson Cancer Center expressed his gratitude to Sandeep for…
Chronic Lymphocytic Leukemia (CLL), a type of cancer that begins in the bone marrow and invades the blood, is one…
Barbara Eichhorst, MD Professor of Medicine at UNIVERSITÄTSKLINIKUM KÖLN, is the author of this OncologyTube.com video. Timestamps: 0:09 Can you…
Chronic Lymphocytic Leukemia (CLL) is a serious condition, and the current standard treatment involves a combination of Ibrutinib and Obinutuzumab…
Dr. Brian Hill, MD, PhD, from the Cleveland Clinic presented a study conducted through the Alliance and US cooperative groups,…
Acalabrutinib (AVO): A Promising New Triplet Treatment Option for High-Risk CLL Patients Phase 2 Study Results Matthew Davids By Matthew…
Zanubrutinib Outperforms Ibrutinib in Treating Relapsed/Refractory CLL/SLL Mehrdad Mobasher MD By Mehrdad Mobasher, MD, MPH The ALPINE study was a…
Zanubrutinib compared to ibrutinib in chronic lymphocytic leukemia By Elizabeth Brém, MD from UCI Health We focused basically on two…
Zanubrutinib compared to ibrutinib in chronic lymphocytic leukemia So I’m gonna start with chronic lymphocytic leukemia. And as part of…
Emerging BTK inhibitors are positioned to change the landscape and impact your chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) treatment…
CLL Treatments: ASH 2022 Brian Koffman Understanding Pts with CLL By Brian Koffman, MDCM (retired), DCFP, FCFP, DABFP, MSEd How…
CLL Treatments: ASH 2022 Brian Koffman Understanding Pts with CLL By Brian Koffman, MDCM (retired), DCFP, FCFP, DABFP, MSEd How…
iFrame is not supported! Nemtabrutinib: Jennifer Woyach, MD ASH 2022 – BELLWAVE-001 Study By Jennifer Woyach, MD What did the…
Nemtabrutinib: Jennifer Woyach, MD ASH 2022 – BELLWAVE-001 Study By Jennifer Woyach, MD What did the BELLWAVE-01 study on Nemtabrutinib…
Zanubrutinib: Superior PFS in CLL Jennifer Brown, MD – ASH 2022 By Jennifer Brown, MD I’ll be discussing the alpine…
Calquence Tablet FDA Approved CLL, SLL, MCL Can You Tell Us The Significance Of The FDA’s Approval Of Calquence? The…
Professor Peter Hillmen, MD, he leads the Experimental Haematology section in LICAP and the Translational Haematology Research group. He is…
So, I presented the interim analysis of the second part of the FLARE trial, which is a randomized phase 3…
Priyanka A. Pophali, MD, Assistant Professor, Division of Hematology at the University of Wisconsin-Madison. In this video, she speaks about…
Priyanka A. Pophali, MD, Assistant Professor, Division of Hematology at the University of Wisconsin-Madison. In this video, she speaks about…
Lindsey E. Roeker, MD Hematologist Oncologist from Memorial Sloan Kettering Cancer Center speaks about the ASH 2021 Abstract – A…
Lindsey E. Roeker, MD Hematologist Oncologist from Memorial Sloan Kettering Cancer Center speaks about the ASH 2021 Abstract – A…
Paolo Ghia earned his medical degree from the University of Torino and then completed an internal medicine residency. He earned…
Paolo Ghia received his MD from the University of Torino, Italy, and received his PhD working at the Basel Institute…
Paul M. Barr, MD from the University of Rochester Medical Center Department of Neurobiology and Anatomy speaks about the ASCO…
John Pagel, MD from the Swedish Cancer Institute & CLL Society Inc. discusses the ASH 2020 Abstract – 127 Clonal…
Anthony Mato, MD of Memorial Sloan Kettering Cancer Center discusses ASH 2020 abstract – Oral presentation looking at real-world data…
John N. Allan, MD – Assistant Professor of Medicine in the Division of Hematology and Medical Oncology at Weill Cornell…
For the GRACE Blood Cancer Video Library, Dr. Joshua Brody, Assistant Professor of Medicine, Hematology and Medical Oncology and Director…
Paolo Ghia, MD, Ph.D. of Università Vita-Salute San Raffaele speaks about ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib…
John Pagel, MD Swedish Cancer Institute discusses Adaptive Biotechnologies Receives Expanded FDA Clearance for the clonoSEQ® Assay to Assess Minimal…
John Pagel, MD Swedish Cancer Institute discusses Adaptive Biotechnologies Receives Expanded FDA Clearance for the clonoSEQ® Assay to Assess Minimal…
John Pagel, MD Swedish Cancer Institute discusses Adaptive Biotechnologies Receives Expanded FDA Clearance for the clonoSEQ® Assay to Assess Minimal…
Brian Koffman, MD CLL Society Inc. discusses Adaptive Biotechnologies Receives Expanded FDA Clearance for the clonoSEQ® Assay to Assess MRD…
Brian Koffman, MD CLL Society Inc. discusses Adaptive Biotechnologies Receives Expanded FDA Clearance for the clonoSEQ® Assay to Assess MRD…
Brian Koffman, MD CLL Society Inc. discusses Adaptive Biotechnologies Receives Expanded FDA Clearance for the clonoSEQ® Assay to Assess MRD…
Othman Al-Sawaf, MD of University Hospital Cologne discusses fixed-duration venetoclax-obinutuzumab forpreviously untreated patients with CLL: follow-up of efficacy and safety…
Othman Al-Sawaf, MD of University Hospital Cologne discusses fixed-duration venetoclax-obinutuzumab for previously untreated patients with CLL: follow-up of efficacy and…
Othman Al-Sawaf, MD of University Hospital Cologne discusses fixed-duration venetoclax-obinutuzumab for previously untreated patients with CLL: follow-up of efficacy and…
Earn CME: https://www.naccme.com/program/7335-2 In this webcast from the ‘MRD in Hematologic Malignancies: Testing Considerations and Challenges’ symposium, Dr. Steven E.…
Earn CME: https://www.naccme.com/program/19-lm-09 In this webcast from the ‘Understanding Waldenström’s Macroglobulinemia: A Guide to Diagnosis, Risk Stratification, and Current and…
Earn CME: https://www.naccme.com/program/19-lm-09 In this webcast from the ‘Understanding Waldenström’s Macroglobulinemia: A Guide to Diagnosis, Risk Stratification, and Current and…
John Seymour, PhD of @PeterMacCC discusses year analysis of murano study confirms sustained benefit of time-limited venetoclax-rituximab (VenR) in relapsed…
 VENCLYXTO® plus obinutuzumab is the first chemotherapy-free, fixed-duration combination regimen approved by the European Commission (EC) for patients with previously…
Chaitra Ujjani, MD, Associate Professor, @SeattleCCA University of Washington, Fred Hutchinson Cancer Research Center, tells us about the results of…
Constantine Tam, MBBS, MD, Consultant Hematologist, Peter MacCallum Cancer Center, offers his impressions of the Phase 2 CAPTIVATE study investigating…
Tanya Siddiqi, MD, Director, CLL Program, Toni Stephenson Lymphoma Center, Associate Clinical Professor, Department of Hematology, City of Hope, elaborates…